Cargando…

Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints

Criteria used by the National Institute for Health and Care Excellence (NICE) to assess life-extending, end-of-life (EoL) treatments imply that health gains from such treatments are valued more than other health gains. Despite claims that the policy is supported by societal values, evidence from pre...

Descripción completa

Detalles Bibliográficos
Autores principales: McHugh, Neil, van Exel, Job, Mason, Helen, Godwin, Jon, Collins, Marissa, Donaldson, Cam, Baker, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pergamon 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884317/
https://www.ncbi.nlm.nih.gov/pubmed/29276987
http://dx.doi.org/10.1016/j.socscimed.2017.12.019
_version_ 1783311803912028160
author McHugh, Neil
van Exel, Job
Mason, Helen
Godwin, Jon
Collins, Marissa
Donaldson, Cam
Baker, Rachel
author_facet McHugh, Neil
van Exel, Job
Mason, Helen
Godwin, Jon
Collins, Marissa
Donaldson, Cam
Baker, Rachel
author_sort McHugh, Neil
collection PubMed
description Criteria used by the National Institute for Health and Care Excellence (NICE) to assess life-extending, end-of-life (EoL) treatments imply that health gains from such treatments are valued more than other health gains. Despite claims that the policy is supported by societal values, evidence from preference elicitation studies is mixed and in-depth research has shown there are different societal viewpoints. Few studies elicit preferences for policies directly or combine different approaches to understand preferences. Survey questions were designed to investigate support for NICE EoL guidance at national and regional levels. These ‘Decision Rule’ and ‘Treatment Choice’ questions were administered to an online sample of 1496 UK respondents in May 2014. The same respondents answered questions designed to elicit their agreement with three viewpoints (previously identified and described) in relation to provision of EoL treatments for terminally ill patients. We report the findings of these choice questions and examine how they relate to each other and respondents' viewpoints. The Decision Rule questions described three policies: DA – a standard ‘value for money’ test, applied to all health technologies; DB – giving special consideration to all treatments for terminal illnesses; and DC – giving special consideration to specific categories of treatments for terminal illnesses e.g. life extension (as in NICE EoL guidance) or those that improve quality-of-life (QoL). Three Treatment Choices were presented: TA – improving QoL for patients with a non-terminal illness; TB – extending life for EoL patients; and TC – improving QoL at the EoL. DC received most support (45%) with most respondents giving special consideration to EoL only when treatments improved QoL. The most commonly preferred treatment choices were TA (51%) and TC (43%). Overall, this study challenges claims about public support for NICE's EoL guidance and the focus on life extension at EoL and substantiates existing evidence of plurality in societal values.
format Online
Article
Text
id pubmed-5884317
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Pergamon
record_format MEDLINE/PubMed
spelling pubmed-58843172018-04-06 Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints McHugh, Neil van Exel, Job Mason, Helen Godwin, Jon Collins, Marissa Donaldson, Cam Baker, Rachel Soc Sci Med Article Criteria used by the National Institute for Health and Care Excellence (NICE) to assess life-extending, end-of-life (EoL) treatments imply that health gains from such treatments are valued more than other health gains. Despite claims that the policy is supported by societal values, evidence from preference elicitation studies is mixed and in-depth research has shown there are different societal viewpoints. Few studies elicit preferences for policies directly or combine different approaches to understand preferences. Survey questions were designed to investigate support for NICE EoL guidance at national and regional levels. These ‘Decision Rule’ and ‘Treatment Choice’ questions were administered to an online sample of 1496 UK respondents in May 2014. The same respondents answered questions designed to elicit their agreement with three viewpoints (previously identified and described) in relation to provision of EoL treatments for terminally ill patients. We report the findings of these choice questions and examine how they relate to each other and respondents' viewpoints. The Decision Rule questions described three policies: DA – a standard ‘value for money’ test, applied to all health technologies; DB – giving special consideration to all treatments for terminal illnesses; and DC – giving special consideration to specific categories of treatments for terminal illnesses e.g. life extension (as in NICE EoL guidance) or those that improve quality-of-life (QoL). Three Treatment Choices were presented: TA – improving QoL for patients with a non-terminal illness; TB – extending life for EoL patients; and TC – improving QoL at the EoL. DC received most support (45%) with most respondents giving special consideration to EoL only when treatments improved QoL. The most commonly preferred treatment choices were TA (51%) and TC (43%). Overall, this study challenges claims about public support for NICE's EoL guidance and the focus on life extension at EoL and substantiates existing evidence of plurality in societal values. Pergamon 2018-02 /pmc/articles/PMC5884317/ /pubmed/29276987 http://dx.doi.org/10.1016/j.socscimed.2017.12.019 Text en © 2017 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
McHugh, Neil
van Exel, Job
Mason, Helen
Godwin, Jon
Collins, Marissa
Donaldson, Cam
Baker, Rachel
Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
title Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
title_full Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
title_fullStr Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
title_full_unstemmed Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
title_short Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints
title_sort are life-extending treatments for terminal illnesses a special case? exploring choices and societal viewpoints
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884317/
https://www.ncbi.nlm.nih.gov/pubmed/29276987
http://dx.doi.org/10.1016/j.socscimed.2017.12.019
work_keys_str_mv AT mchughneil arelifeextendingtreatmentsforterminalillnessesaspecialcaseexploringchoicesandsocietalviewpoints
AT vanexeljob arelifeextendingtreatmentsforterminalillnessesaspecialcaseexploringchoicesandsocietalviewpoints
AT masonhelen arelifeextendingtreatmentsforterminalillnessesaspecialcaseexploringchoicesandsocietalviewpoints
AT godwinjon arelifeextendingtreatmentsforterminalillnessesaspecialcaseexploringchoicesandsocietalviewpoints
AT collinsmarissa arelifeextendingtreatmentsforterminalillnessesaspecialcaseexploringchoicesandsocietalviewpoints
AT donaldsoncam arelifeextendingtreatmentsforterminalillnessesaspecialcaseexploringchoicesandsocietalviewpoints
AT bakerrachel arelifeextendingtreatmentsforterminalillnessesaspecialcaseexploringchoicesandsocietalviewpoints